For the second quarter of 2026, analysts expect Gyre Therapeutics to report consensus revenue of $26.49 million and an EPS loss of $0.08, while the stock currently trades at $6.40 versus an $18.67 average analyst target.
Investors are primarily focused on the commercial growth of flagship anti-fibrotic drug ETUARY in China and regulatory milestones for lead candidate F351.
Recent performance has been influenced by the May 2026 acquisition of Cullgen, which added targeted protein degrader technology but increased R&D spending. Market participants are also evaluating the company's stability following the termination of its collaboration with Astellas Pharma.